Global healthcare pros prefer live reps, survey finds

Share this article:
For all the talk of e-detailing and digitizing the sales force, a plurality of international healthcare professionals would rather get info about new treatments from flesh-and-blood reps than through any other channel, a survey found.

While results varied by market, on average, half of the 450 European, Chinese, Indian and Latin American healthcare professionals responding to a Digitas Health/Economist Intelligence Unit survey cited sales reps as their preferred source of new drug information. Reps were almost even with conferences (49%), followed by “Independent sources on the Internet” (36%), email from pharma companies (34%), Colleagues and peers (31%), Pharma companies via the Internet (27%) and snail mail from pharmas (22%).

Even in the pharma-skeptical UK, 42% of professionals said they'd prefer to get info on new drugs from reps (even more UK HCPs – 44% -- said they'd like that information in emails from pharma companies). Chinese HCPs were far and away the least rep-friendly, with just 18% expressing a preference for live details and a mere 6% interested in pharma company emails on new drugs.

That's not to say HCPs outside the US are averse to digital communications. Only a quarter of all HCP respondents said information from pharma companies delivered digitally wasn't valuable.

Pharmas didn't even register among the factors HCPs cited as obstacles to doing their jobs and challenges to their nations' healthcare systems – both of which were dominated by funding worries. But when asked what  the most important roles for pharma companies were in addressing their nations' healthcare challenges, the largest number – 59% -- said “Offering cheaper drugs.” That was followed by drugs for unmet medical needs (33%), public health campaigns (32%), improving existing drugs (31%) and availability of drugs (25%).   

 
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...